Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background

Fostair in Asthma

trimbow_subheader-mobile

Fostair is available in the following presentations for maintenance therapy of adult asthma, each delivering 120 inhalations per device.1-4

  • Fostair NEXThaler 100/6
  • Fostair NEXThaler 200/6
  • Fostair pMDI 100/6
  • Fostair pMDI 200/6

Fostair pMDI 100/6 and Fostair NEXThaler 100/6 are also available for use in maintenance and reliever therapy (MART) in adult asthma.1,3

Fostair® NEXThaler and pMDI device images for 100/6 & 200/6

Fostair is available in the following presentations for maintenance therapy of adult asthma, each delivering 120 inhalations per device.1-4

  • Fostair NEXThaler 100/6
  • Fostair NEXThaler 200/6
  • Fostair pMDI 100/6
  • Fostair pMDI 200/6

Fostair pMDI 100/6 and Fostair NEXThaler 100/6 are also available for use in maintenance and reliever therapy (MART) in adult asthma.1,3

Flexibility with Fostair for your adult asthma patients
Flexibility with Fostair for your adult asthma patients

Adapted from BTS/SIGN British guideline on the management of asthma 2019.5

Comparable efficacy
  • Fostair NEXThaler has demonstrated comparable efficacy to Fostair pMDI across a variety of lung function measures and asthma control1,2,6
  • Both Fostair pMDI and Fostair NEXThaler are characterised by an extrafine particle size distribution1–4

100mcg of extrafine beclometasone in Fostair is equivalent to 250mcg of non-extrafine beclometasone3,4

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.

Click here for Clenil® (beclometasone) Prescribing Information.

Click here for Fostair® (beclometasone/formoterol) Prescribing Information.

b.d.: twice daily; BTS: British Thoracic Society; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene receptor antagonist; MART: maintenance and reliever therapy; pMDI: pressurised metered dose inhaler; SIGN: Scottish Intercollegiate Guidelines Network.

References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
5. British Thoracic Society (BTS). BTS/SIGN British Guideline on the Management of Asthma 2019. Available at: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Accessed June 2020.
6.Kanniess F, et al. Pulm Pharmacol Ther. 2015; 30: 121–127.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.